Filing Flows › Ideaya Biosciences (IDYA) › Q1 2026
Ideaya Biosciences (IDYA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Ideaya Biosciences (IDYA) reported revenue of $6.6M for the first quarter 2026 (Q1 2026) and -40% from the quarter before.
Ideaya Biosciences, Q1 2026: revenue $6.6M, net loss $98.5M, operating cash flow −$75.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.6M | -40% | — |
| Operating profit | −$109M | — | — |
| Net earnings | −$98.5M | — | — |
| Operating cash flow | −$75.2M | — | — |
What changed
Revenue was $6.6M in Q1 2026, down 40% from the previous quarter.
Operating costs exceeded revenue by $108.5M, an operating margin of -1654.6%. The quarter ended with a net loss of $98.5M, wider than the previous quarter's $83.3M loss.
Operating cash flow was −$75.2M. Non-cash charges added back $688K of depreciation and amortization and $14.5M of share-based compensation. Working capital and other items added $8.1M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$76.1M.
Questions
What was Ideaya Biosciences' revenue in the first quarter 2026?
Ideaya Biosciences (IDYA) reported revenue of $6.6M for the first quarter 2026 (Q1 2026) and -40% from the quarter before.
Source: Ideaya Biosciences 10-Q on SEC EDGAR.